Year

2012

Status

Exited

Team

Field

Cardiovascular therapeutic

Location

Amsterdam (The Netherlands)

Fund

BGV II

Dezima Pharma

Dezima Pharma develops a best in class CETP inibitor for the treatment of cardiovascular disease. DEzima Pharma was acquired by Amgen in 2015.